Beyond Air, Inc. XAIR 深 沪
等待开盘 04-01 09:30:00 美东时间
0.6902
+0.018
+2.66%
华盛通- 最 高0.7093
- 今 开0.67
- 成交量 7.11万股
- 最 低 0.67
- 昨 收 0.6723
- 总市值 726.74万
- 52周最高 5.842
- 市盈率 静 --
- 换手率 0.68%
- 52周最低 0.6666
- 委 比 79.59%
- 总股本 1052.93万
- 历史最高 328.20
- 量 比 0.54
- 振 幅 5.85%
- 历史最低 0.6666
- 每 手 1
- 风险率 1.28%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Beyond Air CEO Steve Lisi Resigns, Effective March 27; Robert Goodman Appointed Successor
Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients,
03-27 04:19
Beyond Air, Inc. Announces Resignation of Steve Lisi, CEO, and Appointment of Robert Goodman, Chief Commercial Officer, as CEO
Beyond Air, Inc. announced that Steve Lisi has resigned as CEO and has been replaced by Robert Goodman, the current Chief Commercial Officer and Director.李西在任期间成功推出LungFit PH技术，为公司奠定了增长基础。Goodman拥有丰富的商业和运营经验，将在推动LungFit PH市场采用和商业规模扩展方面发挥关键作用。公司表示领导层过渡将平稳进行，不会影响运营和战略优先事项。
03-26 20:05
Beyond Air's Subsidiary Beyond Cancer Announces Early Signs Of Clinical Activity And Safety And Tolerability Profile From Phase 1 Clinical Trial Evaluating Single Intratumoral UNO Injection Administered As Monotherapy
Beyond Cancer, Ltd., a clinical stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an investigational immunotherapeutic for solid tumors and subsidiary of Beyond Air, Inc.
03-18 04:37
Beyond Cancer Reports Early Clinical Activity and Favorable Safety Profile with Interim Data from Phase 1 UNO Trial
Beyond Cancer Ltd., a subsidiary of Beyond Air Inc., announced positive early results from its Phase 1 trial of ultra-high concentration nitric oxide (UNO) as a potential immunotherapy for solid tumors. The trial showed favorable safety profiles and evidence of clinical activity in heavily pretreated patients, with six patients achieving no evidence of disease. These findings will be presented at the AACR Annual Meeting 2026. The company believes...
03-17 20:35
Beyond Air halts sale of NeuroNOS subsidiary to XTL Biopharmaceuticals
Beyond Air (XAIR) has terminated an agreement with XTL Biopharmaceuticals to sell its majority ownership interest in NeuroNOS subsidiary The companies had entered into a letter of intent in January ...
03-10 19:59
Beyond Air® Announces Termination of Agreement to Sell Its NeuroNOS Subsidiary to XTL Biopharmaceuticals Ltd.
Beyond Air, Inc. has terminated its proposed transaction with XTL Biopharmaceuticals Ltd. regarding its NeuroNOS subsidiary. The letter of intent expired on March 9, 2026, and no definitive agreement was reached. Beyond Air remains committed to maximizing the value of NeuroNOS and advancing its core nitric oxide platform and LungFit programs.
03-10 11:30
XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing
XTL Biopharmaceuticals Ltd. has received a delisting notice from Nasdaq, citing the company as a "public shell" due to its wholly owned subsidiary, The Social Proxy, being liquidated. The company plans to request a hearing to appeal the delisting decision, which would temporarily prevent the suspension of its ADSs. Additionally, the company failed to meet shareholder equity and bid price requirements, further supporting Nasdaq's delisting decisio...
02-27 21:30
Beyond Air Comments On Independent Review Of Nitrous Oxide Respiratory Treatments
XAIR believes the publication of this article will serve as a catalyst for new scientific research and accelerate the clinical development of high‑dose iNO as a potential transformative treatment modality for pulmonary
02-20 21:06
Beyond Air Reports Strong Q3 Growth and Funding Extension
The latest announcement is out from Beyond Air ( ($XAIR) ). On February 13, 202...
02-14 05:52
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers CytoMed Therapeutics (NASDAQ:GDTC) shares moved upwards by 6.9% to $1....
02-14 05:06
